NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of first-in-class carbohydrate therapeutics, today announced it has signed an agreement with Digna Biotech SL of Pamplona, Spain to investigate the application of the Company’s carbohydrate technology platform in combination with Digna’s novel drugs to improve treatment of chronic Hepatitis C infections. The investigation will evaluate the ability of carbohydrate compounds to improve the delivery of Digna’s novel compounds to enhance activity against chronic Hepatitis C infections. Pro-Pharmaceuticals’ lead compound DAVANAT® will be the first carbohydrate compound to be evaluated as data from pre-clinical and clinical trials show that DAVANAT® increased the patient’s exposure to 5-FU ten-fold with no increase in toxicity.
